Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 121

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 121
---
 pro-inflammatory cytokines compared to a CD20-TCE in PBMCs from HD.

• IPH6501 advantage over antibody-based CD20-targeting therapies: NK cells from B-NHL patients lymph nodes express low levels of CD16 while NKp46 is maintained

•IPH6501 has applications across subtypes of B-NHL, and potential in post CAR-T setting:

◦IPH6501 targets (NKp46, CD16, IL-2Rβ) are expressed on blood NK cells

◦IPH6501 shows potent in vitro antitumor activity on patient PBMCs

◦ Post-lymphodepletion NK recovery (Piperoglou et al., 2021, J. Leuk. Biol) supports IPH6501 potential in post CAR-T patients.

IPH6501 is a first-in-class CD20-targeting tetra-specific NK cell engager designed to promote NK cell proliferation and specific cytotoxicity against CD20+ cells. IPH6501 is thus a promising biologic designed to harness the anti-tumor functions of NK cells in CD20+ B cell malignancies.

d. Clinical Trial

An international, first-in-human, multicenter, open-label Phase 1/2 study will evaluate the safety profile, tolerability of IPH6501, and determine the recommended Phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma. The Company received a Study May Proceed Letter from FDA in July 2023.

On March 6, 2024, the Company announced that the first patient was dosed in its Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell non-Hodgkin’s lymphoma. The study is ongoing and planned to

enroll up to 184 patients. Clinical sites are open in the US, Australia and France and the first safety and preliminary activity data are expected in late 2025.

A poster on the design of the ongoing trial was presented at ASCO 2024.

In December 2024, the Company has entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL) with the Institute for Follicular Lymphoma (IFLI) under which Innate’s ongoing Phase 1/2